Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson’s Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study

Table 1

Demographic and clinical features at baseline.

Characteristic	Rotigotine ( = 62)
Age, years	70.2 ± 7 (48–83)
Male, (%)	41 (66.1)
Education, years	9.1 ± 4 (2–20)
Disease duration, years	5.7 ± 4 (0.5–24)
UPDRS-III	23 ± 10 (5–60)
Hoehn and Yahr	2.2 ± 0.8 (1–4)
Total LEDD, mg/day	526 ± 436 (0–1800)
GDS-15	5 ± 4 (0–15)
Total PDSS-2 score	23.5 ± 9 (10–46)
PD-SFQ	10.1 ± 3 (5–20)
Rotigotine dose, mg/day	8.5 ± 3 (4–16)

All values are mean ± standard deviation (range) unless otherwise stated.
GDS-15, Geriatric Depression Scale; LEDD, levodopa equivalent daily dose; PD-SFQ, Parkinson’s Disease Sleep Fragmentation Questionnaire; PDSS-2, Parkinson’s Disease Sleep Scale; UPDRS, Unified Parkinson’s Disease Rating Scale.